- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04232306
Liposomal Bupivacaine + Bupivacaine vs. Bupivacaine Alone on Opioid Use After Elective c/Section
The Effect of Liposomal Bupivacaine Plus Bupivacaine Versus Bupivacaine Alone on Postoperative Opioid Use After Elective Cesarean Delivery: a Randomized Control Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pain in the postpartum period is an important concern of new mothers. With over one-third of deliveries ending in cesarean section, effective postoperative pain control is essential in the care of postpartum patients.1 Improved pain control in the postpartum period after cesarean delivery (CD) is associated with improved overall maternal health and satisfaction, decreased postpartum depression, shortened hospital stay, decreased opioid consumption, and decreased healthcare costs, as well as possible facilitation of early contact of mothers with their infants.2 Pain control is of great concern to women during and after cesarean delivery.3 Pain relief and patient satisfaction are inadequate in many cases. Pain may be severe, last at least 48-72 hours, and may impair early postoperative recovery.
Opioids are primarily used in the post-operative period. Although opioids are safe to use in breastfeeding mothers, they are not without unwanted side effects.4 Local anesthetics and parenteral NSAIDs are also beneficial adjuncts to regional or general anesthesia after CD by reducing opioid consumption and improving pain relief.5 In addition, field block with wound infiltration with local anesthetic is an effective and safe adjunct for pain control. Previous studies have shown improved postoperative pain control with TAP (transversus abdominis plane) blocks with bupivacaine in hysterectomy patients.4 Another study has looked at the effects of bupivacaine-soaked spongostan placed in cesarean wounds.2 EXPAREL®® (Parsippany, NJ: Pacira Pharmaceuticals, Inc) is a liposomal form of bupivacaine. Its mechanism of action is by DepoFoam® technology, in which microscopic, polyhedral molecules that contain aqueous chambers with liposomal bupivacaine that are slowly released over hours to days with erosion and rearrangement of lipid membranes.6 The slow release of local anesthetic extends its pharmacologic effect and provides longer postsurgical pain control for up to 72 hours.6 This method of delivery of local anesthetic has the potential to decrease postoperative opioid consumption.7 EXPAREL® is an FDA-approved medication for the general use of postoperative surgical site pain control. Paracervical block is the only obstetric contraindication to EXPAREL® use. The purpose of this study is to compare the effectiveness of local wound infiltration of EXPAREL® (liposomal bupivacaine) with bupivacaine HCl compared to active control with bupivacaine HCl alone following elective primary or repeat cesarean delivery with spinal anesthesia. The investigators hypothesize that narcotic use during postoperative hospitalization will be decreased using liposomal bupivacaine.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Amy Boardman, MD
- Phone Number: 7043553153
- Email: amy.boardman@atriumhealth.org
Study Contact Backup
- Name: Deanna Hamm, BS
- Phone Number: 7043557261
- Email: deanna.hamm@atriumhealth.org
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Atrium Health
-
Contact:
- Amy Boardman, MD
- Phone Number: 7043553153
- Email: amy.boardman@atriumhealth.org
-
Contact:
- Deanna Hamm
- Phone Number: 704-355-7261
- Email: deanna.hamm@atriumhealth.org
-
Principal Investigator:
- Lynn Am Boardman, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females 18 years of age and older at screening
- Subjects at 37 completed weeks of gestation or greater undergoing elective primary or repeat cesarean delivery (CD)
- Pfannenstiel incision
- Regional spinal anesthesia
- ASA classification I, II, or III
- Able to give informed consent
- English- or Spanish-speaking
Exclusion Criteria:
- ASA classification IV
- Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, NSAIDs, spinal anesthesia).
- Potential drug interaction(s) with bupivacaine
- Severe renal or hepatic dysfunction manifest as serum creatinine level >2 mg/dL, blood urea nitrogen level >50 mg/dL , serum aspartate aminotransferase level >3 times the upper limit of normal, or serum alanine aminotransferase level >3 times the ULN.
- Any clinically significant maternal or fetal event or condition arising during surgery (eg, excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postsurgical course. In this situation, the subject would be ineligible to receive study drug and withdrawn from the study.
- Chronic pain disorder manifest as a concurrent, painful, physical condition that may require long-term, consistent use of opioids postoperatively for pain that is not strictly related to the surgery and may confound postsurgical assessments.
- History of, suspected, or known addiction or abuse of illicit drug(s) or prescription medication(s) within the past 2 years.
- Planned concurrent surgical procedure except for salpingo-oophorectomy or tubal ligation.
- Subject at increased risk for bleeding or coagulation disorder (defined as platelet count less than 80,000/mm3 or international normalized ratio[INR] greater than 1.5).
- Pregnancy body mass index >50 kg/m2 or otherwise not anatomically appropriate to undergo local incision infiltration.
- Conversion of spinal anesthesia to general anesthesia due to incomplete neuraxial block and unsatisfactory surgical anesthesia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liposomal Bupivacaine + Bupivacaine HCL
Liposomal bupivacaine + bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
|
Bupivacaine liposome injectable suspension
Other Names:
Bupivacaine HCl surgical-site incision infiltration
Other Names:
|
Active Comparator: Bupivacaine HCl surgical-site incision infiltration
Bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
|
Bupivacaine HCl surgical-site incision infiltration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of total opioid MME (milligram morphine equivalents) consumed at 24, 48 and 72hrs post-op
Time Frame: 72 hours
|
3.1 To compare total opioid consumption through 72-hours following EXPAREL® + bupivacaine HCl surgical-site infiltration versus bupivacaine HCl alone at elective primary or repeat cesarean delivery after spinal anesthesia.
3.2 Primary outcome of this study is total opioid consumption measured in milligram morphine equivalents (MME) at 24-, 48- and 72-hours postoperatively and total MME for duration of hospital admission.
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time to initial rescue analgesia administration
Time Frame: 24 hours
|
Time in hours and minutes
|
24 hours
|
Numeric Pain Rating Score at 72 hours Postoperative
Time Frame: 72 hours
|
postoperative pain assessment with NRS (Numeric Pain Rating Score).
NRS score is comprised of 4 pain questions with the patient rating each one on a scale of 0(no pain) to 10(worst pain imaginable).
Lower scores are favorable.
|
72 hours
|
Overall Benefit of Analgesia Score at 72 hours Postoperative
Time Frame: 72 hours
|
postoperative pain assessment with OBAS (Overall Benefit of Analgesia Score).
The OBAS is comprised of 7 questions each being scored by the patient from 0(minimal pain) to 4(maximum imaginable pain).
Each question is then added up to total the overall benefit of analgesia score.
Lower scores are favorable.
|
72 hours
|
Length of hospital stay
Time Frame: 72 hours
|
measured in days and hours
|
72 hours
|
Initiation of breastfeeding
Time Frame: 72 hours
|
yes/no and time to initiation as measured in days and hours
|
72 hours
|
Postpartum depression scores
Time Frame: 72 hours
|
PHQ-9 postpartum depression scores.
Possible range is 0-27.
Lower scores mean less depression.
|
72 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amy Boardman, MD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00081325
- Pro00022425 (Other Identifier: Atrium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Pain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
Clinical Trials on Liposomal bupivacaine
-
Yongtao SunNot yet recruitingPostoperative Analgesia | Thoracic Paravertebral Block | Thoracoscopic LobectomyChina
-
Steven OrebaughPacira Pharmaceuticals, IncCompleted
-
Indiana UniversityCompletedPain, Postoperative | Acute Pain | ThoracicUnited States
-
Vanderbilt University Medical CenterCompletedAnesthesia | Breast Reconstruction | Transverse Abdominis Plane BlockUnited States
-
University of MinnesotaCompleted
-
Indiana UniversityCompleted
-
University of MinnesotaCompleted
-
Mayo ClinicCompletedPain, Postoperative | Brachial Plexus BlockUnited States
-
The University of Hong KongRecruitingShoulder FracturesHong Kong
-
University of California, San FranciscoCompletedPostoperative Pain | Thoracic Diseases | Opioid UseUnited States